GSK Falls After FDA Advisory Panel Fails to Back Cancer Drug

GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

The US Food and Drug Administration’s Oncologic Drugs Advisory Committee voted that the risks from the drug, called Blenrep, outweighed its benefits. Panelists voted 5-to-3 against a combination of Blenrep and the generic cancer drug Velcade and 7-to-1 against its use in tandem with Pomalyst, marketed by Bristol Myers Squibb Co.

Advisers on the committee pointed to concerns with the dosing and associated toxicity. The non-binding vote could influence whether the FDA ...